ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1573815
This article is part of the Research Topic Harnessing Big Data for Precision Medicine: Revolutionizing Diagnosis and Treatment Strategies View all 32 articles
ALDOC promotes neuroblastoma progression and modulates sensitivity to chemotherapy drugs by enhancing aerobic glycolysis
Provisionally accepted
Yunpeng Chen 1 Haixia Zhu 2 Yishu Luo 1 Tianyue Xie 3 Youyang Hu 4 Zhiwei Yan 1 Weichao Ji 1 YaXuan Wang 5* Qiyou Yin 6* Hua Xian 6*- 1 School of Medicine, Nantong University, Nantong, China
- 2 Cancer Research Center Nantong, Nantong Tumor Hospital, Nantong, Jiangsu Province, China
- 3 Department of Endocrinology, Affiliated Hospital of Nantong University, Nantong, China
- 4 Department of Cardiothoracic Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, China
- 5 Department of Urology, Nantong Tumor Hospital, Nantong, China
- 6 Department of Paediatric Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, China
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Neuroblastoma (NB), a malignant extracranial solid tumor, originates from the sympathetic nervous system, and current treatments for high-risk NB remain suboptimal, with a 5-year overall survival rate of less than 50%. NB occurrence is closely associated with glycolysis, and the use of glycolysis inhibitors and modulation of glycolysis-related gene expression have been shown to affect the progression of NB.Herein, using transcriptomic data from NB patients, we identified ALDOC as an independent risk factor for high-risk NB. Protein detection of ALDOC revealed higher expression in NB cells than it in normal cells. Functional cellular experiments demonstrated that interfering with ALDOC suppressed NB cell proliferation and migration. We observed that significant glycolysis inhibition in cells with downregulated ALDOC expression, as indicated by decreased glucose uptake, lactate production, and ATP generation compared with those in control cells. Additionally, lowering ALDOC expression increased NB cell sensitivity to cisplatin and cyclophosphamide, potentially by inhibiting glycolysis. In summary, our study identified a potential mechanism by which ALDOC promotes NB progression by accelerating glycolysis and highlighted the impact of ALDOC expression on NB cell sensitivity to first-line chemotherapy drugs. However, given the complexity of glycolysis regulation and the involvement of numerous glycolysis-related genes, further research is needed to elucidate the specific underlying mechanisms involved.Nevertheless, investigating the role of ALDOC in aerobic glycolysis during NB pathogenesis has significant implications for the development of novel therapeutic strategies.
Keywords: aerobic glycolysis, Neuroblastoma, ALDOC, MYCN, drug sensitivity
Received: 09 Feb 2025; Accepted: 17 Mar 2025.
Copyright: © 2025 Chen, Zhu, Luo, Xie, Hu, Yan, Ji, Wang, Yin and Xian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
YaXuan Wang, Department of Urology, Nantong Tumor Hospital, Nantong, China
Qiyou Yin, Department of Paediatric Surgery, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu Province, China
Hua Xian, Department of Paediatric Surgery, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
